Ascendis Pharma A/S annual shares outstanding
2017
2018
2019
2020
2021
2022
2023
2024
2025
Ascendis Pharma A/S Shares Outstanding History (ASND)
Ascendis Pharma A/S reported 62.0M shares outstanding at the end of fiscal 2025.
View full Ascendis Pharma A/S company overviewAscendis Pharma A/S annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 62.0M | 1.3M | +2.12% |
| 2024 | 2024-12-31 | 60.7M | 3.0M | +5.17% |
| 2023 | 2023-12-31 | 57.7M | 555,144 | +0.97% |
| 2022 | 2022-12-31 | 57.2M | 214,613 | +0.38% |
| 2021 | 2021-12-31 | 56.9M | 3.2M | +5.93% |
| 2020 | 2020-12-31 | 53.8M | 5.8M | +12.01% |
| 2019 | 2019-12-31 | 48.0M | 5.9M | +13.88% |
| 2018 | 2018-12-31 | 42.1M | 5.2M | +13.93% |
| 2017 | 2017-12-31 | 37.0M | — | — |
Ascendis Pharma A/S quarterly shares outstanding
Q4.16
Q4.17
Q2.18
Q3.18
Q4.18
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q4.22
Q4.23
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 65.7M | 5.1M | +8.45% |
| Q1 2026 | 2026-03-31 | 61.8M | 1.4M | +2.33% |
| Q4 2025 | 2025-12-31 | 62.0M | 1.3M | +2.12% |
| Q3 2025 | 2025-09-30 | 61.1M | — | — |
| Q2 2025 | 2025-06-30 | 60.6M | — | — |
| Q1 2025 | 2025-03-31 | 60.4M | — | — |
| Q4 2024 | 2024-12-31 | 60.7M | 3.0M | +5.17% |
| Q4 2023 | 2023-12-31 | 57.7M | 555,144 | +0.97% |
| Q4 2022 | 2022-12-31 | 57.2M | 214,613 | +0.38% |
| Q4 2021 | 2021-12-31 | 56.9M | 3.2M | +5.93% |
| Q3 2021 | 2021-09-30 | 56.9M | 3.5M | +6.48% |
| Q2 2021 | 2021-06-30 | 53.9M | 5.6M | +11.49% |
| Q1 2021 | 2021-03-31 | 53.8M | 5.8M | +12.18% |
| Q4 2020 | 2020-12-31 | 53.8M | 5.8M | +12.01% |
| Q3 2020 | 2020-09-30 | 53.4M | 5.7M | +11.89% |
| Q2 2020 | 2020-06-30 | 48.3M | 800,578 | +1.68% |
| Q1 2020 | 2020-03-31 | 48.0M | — | — |
| Q4 2019 | 2019-12-31 | 48.0M | 5.9M | +13.88% |
| Q3 2019 | 2019-09-30 | 47.7M | 5.7M | +13.58% |
| Q2 2019 | 2019-06-30 | 47.5M | 5.7M | +13.63% |
| Q4 2018 | 2018-12-31 | 42.1M | 5.2M | +13.93% |
| Q3 2018 | 2018-09-30 | 42.0M | — | — |
| Q2 2018 | 2018-06-30 | 41.8M | — | — |
| Q4 2017 | 2017-12-31 | 37.0M | 0 | 0.00% |
| Q4 2016 | 2016-12-31 | 37.0M | — | — |
Ascendis Pharma A/S Share Buyback History
A share buyback, also called a stock repurchase, is when a company uses cash to buy its own shares. Ascendis Pharma A/S share buyback history shows the reported cash used for repurchases. Buybacks can reduce shares outstanding, but issuance, stock-based compensation, acquisitions, and stock splits can change the share count separately.
Ascendis Pharma A/S used €17.4M to repurchase common stock in fy 2025. Across the latest 5 reported fiscal years, total share repurchases were €251.2M. The latest reported quarter showed €51.6M of share repurchases.
| Fiscal year | Period ended | Share repurchases |
|---|---|---|
| 2025 | 2025-12-31 | €17.4M |
| 2024 | 2024-12-31 | €0 |
| 2023 | 2023-12-31 | €106.1M |
| 2022 | 2022-12-31 | €106.1M |
| 2021 | 2021-12-31 | €21.6M |
TickerStat uses SEC-reported cash payments for common-stock repurchases. The amounts describe capital returned through buybacks; they are not a forecast or a measure of the number of shares retired.
Ascendis Pharma A/S shares outstanding trends
Over the last five fiscal years, Ascendis Pharma A/S's shares outstanding moved from 53.8M to 62.0M, a change of 8.2M. The latest reported quarter, Q2 2026, shows 65.7M.
About the metric
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
Calculation and source
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when a stock-split conversion ratio is reported directly or evidenced by a later filing’s restated historical share balance. After repeated reverse splits, an old period can represent less than one current-basis share; this is a split-adjusted equivalent, not a literal historical certificate count. Values remain as reported when no reliable split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Ascendis Pharma A/S source filings ↗